Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07443085

Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery

Dose-Effect Relationship of Dexmedetomidine on Delirium and Cognitive Function After Lower Limb Orthopedic Surgeries for Elderly Patients

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
75 (estimated)
Sponsor
Benha University · Academic / Other
Sex
All
Age
55 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the dose-response relationship of Dexmedetomidine (DEX) in reducing the incidence and severity of postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) in elderly patients. The study compares different doses of DEX against a fentanyl control group in patients undergoing major lower limb orthopedic surgery under general anesthesia to determine the optimal dosage for cognitive protection.

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidine (Low dose)Patients receive a specific low-dose intravenous infusion of Dexmedetomidine during major lower limb orthopedic surgery under opioid-based general anesthesia. The intervention aims to evaluate the dose-response relationship regarding its neuroprotective effects on postoperative delirium (POD).
DRUGDexmedetomidine (High dose)Patients receive a higher-dose intravenous infusion of Dexmedetomidine during the surgical procedure. This arm is designed to determine if higher concentrations of DEX provide a more significant reduction in the incidence and severity of postoperative delirium and cognitive dysfunction compared to the lower dose.
DRUGFentanylPatients in this group receive standard opioid-based general anesthesia using fentanyl without the addition of Dexmedetomidine. This group serves as the baseline to compare the efficacy of DEX in preventing cognitive decline.

Timeline

Start date
2026-02-26
Primary completion
2027-07-01
Completion
2027-10-01
First posted
2026-03-02
Last updated
2026-03-02

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07443085. Inclusion in this directory is not an endorsement.